

FORMATO EUROPEO
PER IL CURRICULUM
VITAE



INFORMAZIONI PERSONALI

Nome Marcello Arca
Indirizzo
Telefono
Fax
E-mail
Nazionalità
Data di nascita
Codice Fiscale

ESPERIENZA LAVORATIVA

- Date (da – a) 2000 -
• Nome e indirizzo del datore di lavoro Sapienza Università di Roma
• Tipo di azienda o settore Facoltà di Medicina
• Tipo di impiego Professore e Medico
• Principali mansioni e responsabilità Professore Associato di Medicina Interna, responsabile del Centro Aterosclerosi, Policlinico Umberto I di Roma

- Date (da – a) 1994 - 2000
• Nome e indirizzo del datore di lavoro Università di Roma La Sapienza, Istituto di Terapia Medica, Centro per l'Arteriosclerosi e Malattie Metaboliche
• Tipo di azienda o settore Facoltà di Medicina
• Tipo di impiego Assistente medico
• Principali mansioni e responsabilità

- Date (da – a) 1991 - 1993
• Nome e indirizzo del datore di lavoro *Department of Molecular Genetics, UT Southwestern Medical Research - Dallas, TX, USA*
• Tipo di azienda o settore
• Tipo di impiego Researcher Assistant
• Principali mansioni e responsabilità Researcher Assistant

- Date (da – a) 1989 -1991
• Nome e indirizzo del datore di lavoro Center for Human Nutrition, UT Southwestern Medical Center – Dallas TX, USA
• Tipo di azienda o settore

<ul style="list-style-type: none"> • Tipo di impiego • Principali mansioni e responsabilità 	<p>Research Fellow Research Fellow</p>																
<ul style="list-style-type: none"> • Date (da – a) • Nome e indirizzo del datore di lavoro • Tipo di azienda o settore • Tipo di impiego • Principali mansioni e responsabilità 	<p>1985 – 1989 Università di Roma La Sapienza, Istituto di Terapia Medica, Centro per l'Arteriosclerosi e Malattie Metaboliche Facoltà di Medicina Medico Membro dello staff della Lipid Clinic</p>																
<p>PARTECIPAZIONE A TRIAL CLINICI</p>	<table border="0"> <tr> <td style="vertical-align: top;"> <p>2013</p> </td> <td style="vertical-align: top;"> <p>A randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of REGN727/SAR236553 in patients with primary hypercholesterolemia who are intolerant to statins</p> </td> </tr> <tr> <td style="vertical-align: top;"> <p>2012</p> </td> <td style="vertical-align: top;"> <p>Studio di fase 3, randomizzato, in doppio cieco, con controllo placebo, a gruppi paralleli per valutare la sicurezza e l'efficacia di due diversi regimi posologici di Mipomersen in pazienti affetti da ipercolesterolemia familiare e colesterolo delle lipoproteine a bassa densità non controllato adeguatamente</p> </td> </tr> <tr> <td style="vertical-align: top;"> <p>2010</p> </td> <td style="vertical-align: top;"> <p>A multicentre, multinational, randomised, doubleblind, pilot, ascending dose for non responder, parallel group study on the therapeutic efficacy and safety of o.d. Zofenopril 30 mg plus HCTZ 12.5 mg vs. Irbersartan 150 mg plus HCTZ 12.5 mg in elderly subjects (age > 65 years) affected by Isolated Systolic Hypertension never treated or non responder to previous antihypertensive therapy (monotherapy or association of maximum two treatments)</p> </td> </tr> <tr> <td style="vertical-align: top;"> <p>2010</p> </td> <td style="vertical-align: top;"> <p>Studio randomizzato, in doppio cieco, per gruppi paralleli, controllato verso placebo per la valutazione della sicurezza ed efficacia di Ezetimibe in monoterapia in bambini (di età compresa fra 6 e 10 anni) con ipercolesterolemia primaria (eterozigote familiare e non familiare) (Fase 3, Protocollo N. P05522)</p> </td> </tr> <tr> <td style="vertical-align: top;"> <p>2010</p> </td> <td style="vertical-align: top;"> <p>Studio di fase III, multicentrico internazionale, randomizzato a gruppi paralleli e in doppio cieco, per valutare la sicurezza cardiovascolare del BI 10773 (10 mg e 25 mg per os una volta al dì) in confronto alle terapie standard in pazienti con diabete mellito di tipo 2 con aumentato rischio cardiovascolare</p> </td> </tr> <tr> <td style="vertical-align: top;"> <p>2009</p> </td> <td style="vertical-align: top;"> <p>Efficacia e sicurezza dell'associazione zofenopril+idroclorotiazide vs. l'associazione irbesartan + idroclorotiazide in pazienti affetti da sindrome metabolica con ipertensione arteriosa non controllata da precedente monoterapia (EUDRA-Ct-2009-012993-10)</p> </td> </tr> <tr> <td style="vertical-align: top;"> <p>2009</p> </td> <td style="vertical-align: top;"> <p>Pfizer International Study A 2581173 – A three year, prospective, open-label, study to evaluate clinical efficacy, safety and tolerability of atorvastatin in children and adolescent with heterozygous familial hypercholesterolemia</p> </td> </tr> <tr> <td style="vertical-align: top;"> <p>2008</p> </td> <td style="vertical-align: top;"> <p>Pfizer International Study A7941005 - A Phase 2a, randomized,</p> </td> </tr> </table>	<p>2013</p>	<p>A randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of REGN727/SAR236553 in patients with primary hypercholesterolemia who are intolerant to statins</p>	<p>2012</p>	<p>Studio di fase 3, randomizzato, in doppio cieco, con controllo placebo, a gruppi paralleli per valutare la sicurezza e l'efficacia di due diversi regimi posologici di Mipomersen in pazienti affetti da ipercolesterolemia familiare e colesterolo delle lipoproteine a bassa densità non controllato adeguatamente</p>	<p>2010</p>	<p>A multicentre, multinational, randomised, doubleblind, pilot, ascending dose for non responder, parallel group study on the therapeutic efficacy and safety of o.d. Zofenopril 30 mg plus HCTZ 12.5 mg vs. Irbersartan 150 mg plus HCTZ 12.5 mg in elderly subjects (age > 65 years) affected by Isolated Systolic Hypertension never treated or non responder to previous antihypertensive therapy (monotherapy or association of maximum two treatments)</p>	<p>2010</p>	<p>Studio randomizzato, in doppio cieco, per gruppi paralleli, controllato verso placebo per la valutazione della sicurezza ed efficacia di Ezetimibe in monoterapia in bambini (di età compresa fra 6 e 10 anni) con ipercolesterolemia primaria (eterozigote familiare e non familiare) (Fase 3, Protocollo N. P05522)</p>	<p>2010</p>	<p>Studio di fase III, multicentrico internazionale, randomizzato a gruppi paralleli e in doppio cieco, per valutare la sicurezza cardiovascolare del BI 10773 (10 mg e 25 mg per os una volta al dì) in confronto alle terapie standard in pazienti con diabete mellito di tipo 2 con aumentato rischio cardiovascolare</p>	<p>2009</p>	<p>Efficacia e sicurezza dell'associazione zofenopril+idroclorotiazide vs. l'associazione irbesartan + idroclorotiazide in pazienti affetti da sindrome metabolica con ipertensione arteriosa non controllata da precedente monoterapia (EUDRA-Ct-2009-012993-10)</p>	<p>2009</p>	<p>Pfizer International Study A 2581173 – A three year, prospective, open-label, study to evaluate clinical efficacy, safety and tolerability of atorvastatin in children and adolescent with heterozygous familial hypercholesterolemia</p>	<p>2008</p>	<p>Pfizer International Study A7941005 - A Phase 2a, randomized,</p>
<p>2013</p>	<p>A randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of REGN727/SAR236553 in patients with primary hypercholesterolemia who are intolerant to statins</p>																
<p>2012</p>	<p>Studio di fase 3, randomizzato, in doppio cieco, con controllo placebo, a gruppi paralleli per valutare la sicurezza e l'efficacia di due diversi regimi posologici di Mipomersen in pazienti affetti da ipercolesterolemia familiare e colesterolo delle lipoproteine a bassa densità non controllato adeguatamente</p>																
<p>2010</p>	<p>A multicentre, multinational, randomised, doubleblind, pilot, ascending dose for non responder, parallel group study on the therapeutic efficacy and safety of o.d. Zofenopril 30 mg plus HCTZ 12.5 mg vs. Irbersartan 150 mg plus HCTZ 12.5 mg in elderly subjects (age > 65 years) affected by Isolated Systolic Hypertension never treated or non responder to previous antihypertensive therapy (monotherapy or association of maximum two treatments)</p>																
<p>2010</p>	<p>Studio randomizzato, in doppio cieco, per gruppi paralleli, controllato verso placebo per la valutazione della sicurezza ed efficacia di Ezetimibe in monoterapia in bambini (di età compresa fra 6 e 10 anni) con ipercolesterolemia primaria (eterozigote familiare e non familiare) (Fase 3, Protocollo N. P05522)</p>																
<p>2010</p>	<p>Studio di fase III, multicentrico internazionale, randomizzato a gruppi paralleli e in doppio cieco, per valutare la sicurezza cardiovascolare del BI 10773 (10 mg e 25 mg per os una volta al dì) in confronto alle terapie standard in pazienti con diabete mellito di tipo 2 con aumentato rischio cardiovascolare</p>																
<p>2009</p>	<p>Efficacia e sicurezza dell'associazione zofenopril+idroclorotiazide vs. l'associazione irbesartan + idroclorotiazide in pazienti affetti da sindrome metabolica con ipertensione arteriosa non controllata da precedente monoterapia (EUDRA-Ct-2009-012993-10)</p>																
<p>2009</p>	<p>Pfizer International Study A 2581173 – A three year, prospective, open-label, study to evaluate clinical efficacy, safety and tolerability of atorvastatin in children and adolescent with heterozygous familial hypercholesterolemia</p>																
<p>2008</p>	<p>Pfizer International Study A7941005 - A Phase 2a, randomized,</p>																

- placebo-controlled, parallel group, multiple-dose study to evaluate the efficacy, safety and tolerability of 12-week oral administration of PF-00734200 tablets to subjects with type 2 Diabetes Mellitus on stable treatment with metformin
- 2007 International Sanofi-Aventis Study L9754 - A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with or without other comorbidities. The Rimon 00962 Study
- 2006 Sanofi-Aventis Study L9754 - Prevalence of metabolic syndrome in different clinical settings: hypertension and dyslipidemia. Association between metabolic syndrome and organ damage. The PROMISE Study
- 2005 Ministero della salute - Progetto multicentrico di valutazione dell'efficacia dell'atorvastatina e degli N-3 PUFA nei pazienti con sindrome metabolica. Studio TREND
- 2005 Pfizer International Study A3841029 - An international, multicenter, open label study to assess the effectiveness of amlodipine-atorvastatin combination in subjects with hypertension and dislipidaemia. The Jewel II Study
- 2004 Pfizer International Study A2581053 - A phase IV, multicenter, randomized, open label study to evaluate the efficacy and safety of atorvastatin versus simvastatin in type 2 diabetic subjects with hypercholesterolemia. The AID Study
- 2001 Pfizer Study A2581007 - Efficacy, safety of atorvastatin vs fenofibrate in the Familial Combined Hyperlipidemia (FCHL). Therapy, randomized, pilot, comparative study

SELEZIONE DELLE PUBBLICAZIONI

1. Arca M, Jokinen H. Low-density lipoprotein receptor mutations in individuals with moderate hypercholesterolemia. *Atherosclerosis* 136; 187-194; 1998
2. Baroni MG, Arca M, D'Andrea MP, Campagna F, Capici F, Urbinati G, Pozzilli P. A common mutation in the InsulinReceptor Substrate-1 gene is a genetic marker for the insulin resistance syndrome in patients with coronary artery disease. *Diabetes* 47 (suppl. 1): A173, 1998
3. Arca M, Pannitteri G, Campagna F, Candeloro A, Montali A, Cantini R, Seccareccia F, Campa PP, Marino B, Ricci G. Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients. *Eur J Clin Invest* 28; 485-90, 1998
4. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M. The Gln-Arg 192 polymorphism of the paraoxonase gene is not associated with coronary artery disease in Italian patients. *Arterioscler, Thromb, Vasc Biol* 18; 1611-6, 1998
5. Zuliani G, Arca M, Signore A, Bader G, Fazio S, Chianelli M, Bellosta F, Campagna F, Montali A, Maioli M, Pacifico A, Ricci G, Fellin R. The metabolic basis of a new form of recessive hypercholesterolemia: The "FH-like" hypercholesterolemia. *Arterioscler, Thromb Vasc Biol* 19, 802-809, 1999
6. Gaddi A, Galetti C, Pauciullo P, Arca M. Familial Combined Hyperlipidemia: expert panel position on diagnostic criteria for clinical

practice. Committee of experts of the Atherosclerosis and Dysmetabolic Disorders Study Group. *Nutr Metab Cardiovasc Dis* 9; 304–311, 1999

7. Baroni MG, D'Andrea MP, Montali A, Pannitteri G, Barillà F, Campagna F, Mazzei E, Lovari S, Seccareccia F, Campa PP, Ricci G, Pozzilli P, Urbinati G, Arca M. A common mutation of the insulin receptor substrate-1 gene is a risk factors for coronary artery disease. *Arterioscler, Thromb and Vasc Biol* 19, 2975–80, 1999
8. Battiloro E, Ombres D, Pascale E, D'Ambrosio E, Verna R, Arca M. Hemochromatosis gene mutations and risk of coronary artery disease. *Eur J Hum Genet* 8; 389–392, 2000
9. Zuliani G, Pacifico A, Ciccarese M, Pintus P, Arca M, Corsini A, Maioli M, Fellin R. Familial Recessive Hypercholesterolemia (FRH). Characterization of 10 homozygotes and 9 obligate heterozygotes. *Atherosclerosis* 151 (Suppl.1) P16–267, 2000
10. Arca M, Campagna F, Montali A, Barillà F, Manieri E, Tanzilli G, Seccareccia F, Campa PP, Ricci G, Pannitteri G. The common mutations in the lipoprotein lipase gene in Italy: Effects on plasma lipids and angiographically assessed coronary atherosclerosis. *Clin Genet* 58; 369–374, 2000
11. Baroni MG, Arca M, Sentinelli F, Buzzetti R, Capici F, Lovari S, Vitale M, Romeo S, Di Mario U. The G972R variant of the Insulin Receptor substrate-1 (IRS-1) gene, body fat distribution and insulin resistance. *Diabetologia* 44;367–372, 2001
12. Arca M, Montali A, Ombres D, Battiloro E, Campagna F, Ricci G, Verna R. Lack of association of the common TaqIB polymorphism in the cholesterol ester transfer protein gene with angiographically assessed coronary atherosclerosis. *Clinical Genetics* 60; 374–380, 2001
13. Garcia CH, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. *Science* 292;1394–1398, 2001
14. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R, Pannitteri G. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. *Eur J Clin Invest* 32: 9-15,2002
15. Arca M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S, Calandra S, Ricci G, Glorioso N, Maioli M, Pintus P, Carru C, Cossu F, Cohen J, Hobbs HH. Autosomal recessive hypercholesterolemia in Sardinia, Italy, and mutation in ARH: a clinical and molecular genetic analysis. *Lancet* 359; 841-847, 2002
16. Wilund KR, Yi M, Campagna F, Arca M, Zuliani G, Fellin R, ho YK, Garcia JV, Hobbs HH, Cohen JC. Molecular mechanism of autosomal recessive hypercholesterolemia. *Hum Mol Genet* 11: 3019–3030; 2002
17. Vohnout B, Di Castelnuovo A, Trotta R, D'Orazio A, Pannitteri G, Montali A, Donati MB, Arca M, Iacoviello L. Interleukin-1 gene cluster polymorphism and risk of coronary artery disease. *Haematologica* 88; 54–60, 2003
18. Zuliani G, Pacifico A, Ciccarese M, Pintus P, Arca M, Corsini A, Maioli M, Fellin R. Familial Recessive Hypercholesterolemia (FRH). Characterization of 10 homozygotes and 9 obligate heterozygotes. *Atherosclerosis* 151 (Suppl.1) P16–267, 200
19. Arca M, Campagna F, Montali A, Barillà F, Manieri E, Tanzilli G, Seccareccia F, Campa PP, Ricci G, Pannitteri G. The common mutations in the lipoprotein lipase gene in Italy: Effects on plasma lipids and angiographically assessed coronary atherosclerosis. *Clin Genet* 58;

369–374, 2000

20. Baroni MG, Arca M, Sentinelli F, Buzzetti R, Capici F, Lovari S, Vitale M, Romeo S, Di Mario U. The G972R variant of the Insulin Receptor substrate-1 (IRS-1) gene, body fat distribution and insulin resistance. *Diabetologia* 44;367–372, 2001
21. Arca M, Montali A, Ombres D, Battiloro E, Campagna F, Ricci G, Verna R. Lack of association of the common TaqIB polymorphism in the cholesterol ester transfer protein gene with angiographically assessed coronary atherosclerosis. *Clinical Genetics* 60; 374–380, 2001
22. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R, Pannitteri G. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. *Eur J Clin Invest* 32: 9-15,2002
23. Wilund KR, Yi M, Campagna F, Arca M, Zuliani G, Fellin R, ho YK, Garcia JV, Hobbs HH, Cohen JC. Molecular mechanism of autosomal recessive hypercholesterolemia. *Hum Mol Genet* 11: 3019–3030; 2002
24. Vohnout B, Di Castelnuovo A, Trotta R, D'Orazio A, Pannitteri G, Montali A, Donati MB, Arca M, Iacoviello L. Interleukin-1 gene cluster polymorphism and risk of coronary artery disease. *Haematologica* 88; 54–60, 2003
25. Fellin R, Zuliani G, Arca M, Pintus P, Pacifico A, Montali A, Corsini A, Maioli M. Clinical and biochemical characterization of patients with autosomal recessive hypercholesterolemia (ARH). *NMCD* 13; 278–286, 2003
26. Filippi E, Sentinelli F, Trischitta V, Romeo S, Arca M, Leonetti F, Di Mario U, Baroni MG. Association of the human adiponectin gene and insulin resistance *Eur J Hum Genet* 12; 199–205, 2003
27. Cipollone F, Toniato E, Martinetti S, Fazio M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo S, Averna M, Arca M, Montali A, Campagna F, Uchino S, Spigonardo F, Taddei S, Virdis A, Ciabattini G, Notarbartolo A, Cuccurullo F, Mezzetti A. A polymorphism in the cyclooxygenase-2 gene as an inherited protective factors against myocardial infarction and stroke. *JAMA* 291:2221–2228, 2004
28. Del Ben M, Burattin M, Arca M, Ceci F, Violi F, Angelico F. Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia. *Am J Med* 117; 803–804, 2004
29. Buzzetti R, Petrone A, Ribaldo MC, Alemanno I, Zavarella S, Mein CA, Maiani F, Tiberti C, Baroni MG, Vecci E, Arca M, Leonetti F, Di Mario U. The common PPAR- γ 2 Prol2Ala variant is associated with greater insulin sensitivity. *Eur J Hum Genet* 12; 1050–1054, 2004
30. Boekholdt SM, Sacks FM, Jukema JW, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, Humphries SE, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montali A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJP. The cholesterol ester transfer protein (CETP) TaqIB variant, HDL cholesterol levels, cardiovascular risk and the efficacy of pravastatin treatment - an individual patient meta-analysis of 13,677 subjects. *Circulation* 111:278–287,2005
31. Filippi E, Sentinelli F, Romeo S, Arca M, Berni A, Tiberti C, Verrienti A, Fanelli M, Fallarino M, Sorropago G, Baroni MG. The adiponectin gene SNP +276G>T is a risk factor for early-onset coronary artery disease (CAD) and associates with lower levels of plasma adiponectin in younger CAD patients (age 50 years). *J Mol Med.* 83:711–9,2005
32. Campagna F, Fioretti F, Burattin M, Romeo S, Sentinelli F, Bifulco M, Sirinian MI, Del Ben M, Angelico F, Arca M. Congenital analbuminemia

attributable to compound heterozygosity for novel mutation in the albumin gene. *Clin Chem.* 51:1256–8,2005

33. Annovazzi A, Bonanno E, De Toma G, Arca M, D'Alessandria C, Marcocchia A, Cucina A, Mather SJ, Spagnoli LG, Violi F, Scopinaro F, Signore A. ^{99m}Tc-Interleukin-2 (^{99m}Tc-IL-2) scintigraphy for the in vivo visualization of lympho-mononuclear cell infiltration in atherosclerotic plaques. *Eur J Nucl Med Mol Imaging.* 33:117–26,2006
34. Sirinian MI, Belleudi F, Campagna F, Ceridono M, Garofalo T, Quagliarini F, Verna R, Calandra S, Bertolini S, Sorice M, Torrisi MR, Arca M. Adaptor protein ARH is recruited to the plasma membrane by low density lipoprotein (LDL) binding and modulates endocytosis of the LDL/LDL receptor complex in hepatocytes. *J Biol Chem.* 280:38416-38423,2005
35. Pisciotta L, Oliva CP, Pes GM, Di Scala L, Bellocchio A, Fresa R, Cantafora A, Arca M, Calandra S, Bertolini S. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison *Atherosclerosis.* 2006;188:398–405,2006
36. Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, Antonini TM, Antonini R, Diczfalusy U, Iuliano L. Increased oxidative stress in patients with familial combined hyperlipidemia (FCHL): amelioration with lipid-lowering treatment. *Free Radical Biology and Medicine* 42; 698-705, 2007
37. Arca M, Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. *Drugs* 1:29-42,2007
38. Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. *Drugs* 1:43-54,2007
39. Arca M. Atorvastatin. A safety and tollerability profile. *Drugs* 1:63-69,2007
40. Quagliarini F, Vallvé JC, Campagna F, Alvaro A, Fuentes-Jimenez FJ, Sirinian MI, Meloni F, Masana L, Arca M. Autosomal recessive hypercholesterolemia in Spanish kindred due to a large deletion in the ARH gene. *Molecular Genetics and Metabolism* 92:243-248,2007
41. Cipollone F, Martinetti S, Fazia ML, Iezzi A, Cuccurullo C, Ursi S, Averna M, Arca M, Montali A, Campagna F, Uchino S, Spigonardo F, Notarbartolo A, Chiarelli F, Cuccurullo F, Mezzetti A, Toniato E. 5-lipoxygenase variant genotype as an inherited risk factor for myocardial infarction modifiable by n-3 polyunsaturated fatty acid supplementation. *Circulation* (accepted 2007)
42. Arca M, Montali A, Pigna G, Antonimi R, Antonini TM, Petramala L, Mastrantoni M, Maddaloni M, Letizia C. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hypercholesterolemia. *Metabolism* 56:1534-1541,2007
43. Arca M, Montali A, Valiante S, Campagna F, Pigna G, Paoletti V, Antonini R, Barillà F, Tanzilli G, Vestri A, Gaudio C. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. *Am J Cardiol* 2007;100:1511-1516
44. Arca M, Conti B, Montali A, Pignatelli P, Campagna F, Verna R, Vestri A, Gaudio C, Violi F. C242T polymorphism of NADPH Oxidase p22phox, markers of oxidative stress and recurrences of cardiovascular events in patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 2008;28:752-777
45. Campagna F, Martino F, Bifolco M, Montali A, Martino E, Morrone F,

- Antonini R, Cantafora A, Verna R, Arca M. Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening. *Atherosclerosis* 2008; 196:356-364 (doi:10.1016/j.atherosclerosis.2006.11.015)
46. Bruno C, Bertini E, Di Rocco M, Cassandrini D, Ruffa G, De Toni T, Seri M, Spada M, Li Volti G, D'Amico A, Trucco F, Arca M, Casali C, Angelini C, DiMauro S, Minetti C. Clinical and genetic characterization of Chanarin-Dorfman Syndrome. *Biochemical and Biophysical Research Communications* 2008; 369:1125-1128
47. Daphne L. van der A D, Rovere MM, Grobbee DE, Marx JJM, Waalen J, Ellervik C, Nordestgaard BG, Olynyk JK, Mills PR, Shepherd J, Grandchamp B, Boer JMA, Caruso C, Arca M, Meyer BJ, van der Schouw YT. Mutations in the HFE gene and cardiovascular disease Risk: an individual patient data meta-analysis of 53880 subjects. *Circ Cardiovasc Genet* 2008; 1:43-50
48. Campagna F, Nanni L, Quagliarini F, Pennisi E, Michailidis C, Pierelli F, Bruno C, Casali C, DiMauro S, Arca M. Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy *Biochem Biophys Res Commun.* 2008 Dec 19;377(3):843-6. Epub 2008 Oct 24
49. Napoli A, Catalano C, Francone M, Sciacca V, Carbone I, Greco C, Anzidei M, Calabrese FA, Marincola BC, Kirchin MA, Vestri A, Arca M, Iuliano L, Passariello R. Imaging coronary and extracoronary atherosclerosis: feasibility and impact of whole-body computed tomography angiography *Eur Radiol.* 2009 Jul;19(7):1704-14. Epub 2009 Mar 11. [Epub ahead of print]
50. Arca M, Cambuli VM, Montali A, Sentinelli F, Filippi E, Campagna F, Quagliarini F, Antonini R, Romeo S, Baroni MG. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipemic relatives and is influenced by lipid-lowering treatment. *Nutr Metab Cardiovasc Dis* 2009 doi 10.1016/j.numecd.2008.11.008
51. Filigheddu F, Quagliarini F, Campagna F, Secci T, Degortes S, Zaninello R, Giuseppe Argiolas G, Verna R, Silvia Pitzoi S, Frau F, Troffa C, Bulla E, Bertolini S, Glorioso, Arca M. Prevalence and clinical features of heterozygous carriers of autosomal recessive hypercholesterolemia in Sardinia. *Atherosclerosis.* 2009, doi 10.1016/j.atherosclerosis.2009.04.027
52. Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C, Frigerio B, Amato M, Sirtori CR, Alessandrini P, Arca M, Boscutti G, Cattin L, Gesualdo L, Sampietro T, Vaudo G, Veglia F, Calandra S, Franceschini G. Functional lecithin:cholesterol acyltransferase is not required for efficient atheroprotection in humans. *Circulation.* 2009 Aug 18;120(7):628-35
53. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, Shah T, Sandhu MS, Ricketts SL, Boekholdt SM, Wareham N, Khaw KT, Kumari M, Kivimaki M, Marmot M, Asselbergs FW, van der Harst P, Dullaart RP, Navis G, van Veldhuisen DJ, Van Gilst WH, Thompson JF, McCaskie P, Palmer LJ, Arca M, Quagliarini F, Gaudio C, Cambien F, Nicaud V, Poirer O, Gudnason V, Isaacs A, Witteman JC, van Duijn CM, Pencina M, Vasani RS, D'Agostino RB Sr, Ordovas J, Li TY, Kakko S, Kauma H, Savolainen MJ, Kesäniemi YA, Sandhofer A, Paulweber B, Sorli JV, Goto A, Yokoyama S, Okumura K, Horne BD, Packard C, Freeman D, Ford I, Sattar N, McCormack V, Lawlor DA, Ebrahim S, Smith GD, Kastelein JJ, Deanfield J, Casas JP. Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms. *Circulation*

2010;121:52-62

54. Noto D, Cefalù A, Barraco G, Martino E, Fayer F, Minà M, Montali A, Arca M, Averna M, Martino F. Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. *Pediatr Res* 2010;67:200-206
55. Montali A, Barillà F, Tanzilli G, Vestri A, Fraioli A, Gaudio C, Martino F, Mezzetti A, Cipollone F, Arca M. The functional rs20417 SNP (-765G>C) of cyclooxygenase-2 gene does not predict the risk of recurrence of ischemic events in coronary patients: results of a 7- year prospective study. *Cardiology* 2010 (accepted)
56. Glaudemans AWJM, Slart RHJA, Bozzao A, Bonanno E, Arca M, Dierckx RAJO, Signore A. Molecular Imaging in Atherosclerosis. *Eur J Nucl Med Mol Imag* 2010 (accepted)
57. Nanni L, Quagliarini F, Megiorni F, , Montali A, Minicocci I, Campagna F, Pizzuti A, Arca M. Genetic variants in adipose triglyceride lipase influence lipid levels in familial combined hyperlipidemia. *Atherosclerosis* 2010;213 : 206–211
58. Colivicchi F, Di Roma A, Uguccioni M, Scotti E, Ammirati F, Arca M, Avallone A, Bonaccorso o, Germanò G, Letizia C, Manfellotto D, Minardi G, Pristipino C, D'Amore F, Di Veroli C, Fiero A, Pastorelli R, Tozzi Q, Tubaro M, Santini M. Prevenzione cardiovascolare secondaria dopo sindrome coronarica cuta nella pratica clinica. *G Ital Cardiol* 2010; 11 (suppl 4): 3S-29S
59. Giovanni Pigna G, Alessandro Napoli A, Fulvio taccagna F, Cavallo Marincola B, MD, Roberto Monticalo R, Catalano C, Iuliano L, Arca M. The relationship between Metabolic Sindrome, its componets and the whole body atherosclerotic disease burden as measured by computer tomography angiography. *Atherosclerosis* 2011; 215: 417-420 DOI 10.1016/j.atherosclerosis.2010.12.038
60. Arca M, Quagliarini F, Pigna G, Catalano C, Napoli A. Severe coronary and extracoronary atherosclerosis in Autosomal Recessive Hypercholesterolemia (ARH) detected by whole-body computed tomography angiography. *Intern Emerg Med* 2011 Dec;6(6):571-3. Epub 2011 Mar 5; DOI 10.1007/s11739-011-0550-6
61. Pacifico L, Anania C, Martino F, Poggiogalle E, Chiarelli F, Arca M, and Chiesa C. Management of metabolic syndrome in children and adolescents. *Nutr Metab Cardiovasc Dis* 2011; 21: 455-466 doi:10.1016/j.numecd.2011.01.011
62. Marcello Arca M, Pigna G. Treating the statin-intolerant patients. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. *Diabetes Metab Syndr Obes*. 2011;4:155-66. Epub 2011 Apr 28 2011 , doi. org/10.2147/DMSO.S11244
63. Degli Esposti, L., Sangiorgi, D., Arca, M., Vigna, G.B., Budal, S., Degli Esposti, E. Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) Study. *Monaldi Arch Chest Disease* 2011; 76:160-167
64. Arca M, Pigna G, Favocchia C. Management of statin-intolerant patient. *Panminerva Med*. 2012 Jun;54(2):105-18
65. Gianfagna F, Tamburrelli C, Vohnout B, Crescente M, Izzi B, Pampuch A, De Curtis A, Di Castelnuovo A, Cutrone A, Napoleone E, Tayo B, Lorenzet R, Nanni L, Arca M, Donati MB, de Gaetano G, Cerletti C, Iacoviello L. Heritability, genetic correlation and linkage to the 9p21.3 region of mixed platelet-leukocyte conjugates in families with and without early myocardial infarction. *Nutr Metab Cardiovasc Dis*. 2012 May 25. [Epub ahead of print] doi:10.1016/j.numecd.2012.02.008

66. Ilenia Minicocci, Anna Montali, Marius R. Robciuc, Fabiana Quagliarini, Vincenzo Censi, Giancarlo Labbadia, Claudia Gabiati, Giovanni Pigna, Laura Sepe, Fabio Pannozzo, Dieter Lutjohann, Sergio Fazio, Matti Jauhiainen, Christian Ehnholm, Marcello Arca. Mutations in the ANGPTL3 Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization. *J Clin Endocrinol Metab* 2012;97:E1266-75.
67. L. Pacifico, Arca M, C. Anania, V. Cantisani, M. Di Martino, C. Chiesa. Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease.. *Nutr Metab Cardiovasc Dis.* (2012), doi.org/10.1016/j.numecd.2012.08.003
68. Arca M, Favocchia C, Pigna G, Pathophysiology of diabetic dyslipidemia: implication for atherogenesis. *Curr Vasc Pharmacol* 2012; 10: 1-3
69. Taviani D, Missaglia S, Redaelli C, Pennisi ME, Invernici G, Wessalowski R, Maiwald R, Arca M and Coleman RA. Contribution of novel ATGL missense mutations to the clinical phenotype of NLSM: a strikingly low amount of lipase activity may preserve cardiac function. *Hum Molecular Genetics* 2012 (accepted)
70. Arca M. La diagnosi e la terapia delle dislipidemie, in *Dietetica e Nutrizione. Clinica Terapia ed Organizzazione* (Editori Fatati G, Amerio ML). Il Pensiero Scientifico Editore, pg 583-598
71. Fiorillo C, Brisca G, Cassandrini D, Scapolan S, Astrea G, Valle M, Scuderi F, Trucco F, Natali A, Magnano G, Gazzero E, Minetti C, Arca M, Santorelli FM, Bruno C. Subclinical myopathy in a child with neutral lipid storage disease and mutations in the PNPLA2 gene. *Biochem Biophys Res Commun.* 2013 Jan 4;430(1):241-4. doi: 10.1016/j.bbrc.2012.10.127. Epub 2012 Nov 9
72. Arca M, Salvia E, Pigna G Current challenges in the management of patients with familial hypercholesterolemia. *Clin Lipidol* 2013; 8(2):217-229, doi:10.2217/CLP.13.12
73. Minicocci I, Cantisani V, Poggiogalle E, Favari E, Zimetti F, Montali A, Labbadia G, Pigna G, Pannozzo F, Zannella A, Ceci F, Ciociola E, Santini S, Maranghi M, Vestri A, Ricci P, Bernini F, Arca M. Functional and morphological vascular changes in subjects with familial combined hypolipidemia: An exploratory analysis. *Int J Cardiol.* 2013 May 27. pii: S0167-5273(13)00962-5. doi: 10.1016/j.ijcard.2013.05.053.
74. Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A, Arca M, Ehnholm C, Jauhiainen M. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. *Arterioscler Thromb Vasc Biol.* 2013 Jul;33 (7):1706-13. doi: 10.1161/ATVBAHA.113.301397. Epub 2013 May 9
75. Natali A, Gastaldelli A, Camastra S, Baldi S, Quagliarini F, Minicocci I, Bruno C, Pennisi E, Arca M. Metabolic consequences of adipose triglyceride lipase deficiency in humans: an in vivo study in patients with Neutral Lipid Storage Disease with Myopathy. *J Clin Endocrinol Metab.* 2013; 98 (9):E1540-1548
76. Arca M, Minicocci I, Maranghi M. The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism. *Curr Opin Lipidol.* 2013 Aug ;24 (4):313-20. doi: 10.1097/MOL.0b013e3283630cf0
77. Sentinell F, Minicocci I, Montali A, Nanni L, Romeo S, Incani M, Cavallo G, Lenzi A, Arca M, Baroni MG. Association of RXR-gamma gene variants with Familial Combined Hyperlipidemia (FCHL): genotype and haplotype analysis. *Journal of Lipids* 2013
78. Maranghi M, Tiseo G, Arca M. Does Liver derived ANGPTL3 play a role in cardiometabolic risk? Current evidence and future perspectives, *Clin*

Lipidol December 2013, Vol. 8, No. 6 , Pages 615-618; doi: 10.2217/clp.13.66

79. Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A, Arca M, Ehnholm C, Jauhainen M. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. *Arterioscler Thromb Vasc Biol.* 2013 Jul;33 (7):1706-13. doi: 10.1161/ATVBAHA.113.301397. Epub 2013 May 9
80. Natali A, Gastaldelli A, Camastra S, Baldi S, Quagliariini F, Minicocci I, Bruno C, Pennisi E, Arca M. Metabolic consequences of adipose triglyceride lipase deficiency in humans: an in vivo study in patients with Neutral Lipid Storage Disease with Myopathy. *J Clin Endocrinol Metab.* 2013; 98 (9):E1540-1548
81. Arca M, Minicocci I, Maranghi M. The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism. *Curr Opin Lipidol.* 2013 Aug; 24 (4):313-20. doi: 10.1097/MOL.0b013e3283630cf0
82. Sentinell F, Minicocci I, Montali A, Nanni L, Romeo S, Incani M, Cavallo G, Lenzi A, Arca M, Baroni MG. Association of RXR-gamma gene variants with Familial Combined Hyperlipidemia (FCHL): genotype and haplotype analysis. *Journal of Lipids* 2013; 517943. doi: 10.1155/2013/517943. Epub 2013 Oct 13
83. Minicocci I, Santini S, Cantisani V, Stitzel N, Kathiresan S, Arroyo JA, Marti' G, Pisciotta L, Noto D, Maranghi M, Cefalu AB, Labbadia G, Pigna G, PannoZZo F, Ceci F, Ciociola E, Bertolini S, Calandra S, Tarugi P, Averna M, Arca M. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. *J Lipid Res.* 2013. 54: 3481–3490. DOI:10.1194/jlr.P039875
84. Conti F, Spinelli FR, Alessandri C, Pacelli M, Ceccarelli F, Marocchi E, Montali A, Capozzi A, Buttari B, Profumo E, Sorice M, Arca M, Valesini G, Riganò R. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome. A focus on β 2GPI-specific T cell response. *Arterioscler Thromb Vasc Biol.* 2014 Mar;34(3):661-8. doi: 10.1161/ATVBAHA.113.302680. Epub 2014 Jan 16
85. Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, Betteridge DJ, Bhatnagar D, Bilianou E, Carmena R, Češka R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maher V, Marques da Silva P, Masana L, Odawara M, Pedersen TR, Rotella CM, Salti I, Teramoto T, Tokgozoglu L, Toth PP, Valensi P, Vergès B. The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. *Atheroscler Suppl.* 2014 Jun; 15(1):1-15. doi: 10.1016/j.atherosclerosissup.2014.04.001.
86. Ambrosetti M, Malfatto G, Maria Cremona A, Arca M, Faggiano P. Familial hypercholesterolemia in cardiac rehabilitation: a new field of interest. *Monaldi. Arch Chest Dis.* 2014 Jun;82(2):87-92.
87. Del Ben M, Polimeni L, Brancorsini M, Di Costanzo A, D'Erasmo L, Baratta F, Loffredo L, Pignatelli P, Violi F, Arca M, Angelico F. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. *Eur J Intern Med* 2014; 53:566-570, doi: 10.1016/j.ejim.2014.05.012. Epub 2014 Jun 16
88. Fellin R, Arca M, Zuliani G, Calandra S, Bertolini S. The history of Autosomal Recessive Hypercholesterolemia (ARH): from clinical observation to gene identification. *Gene* 2015; 555:23-32, doi.org/10.1016/j.gene.2014.09.020

89. Arca M. Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome *Atheroscler Suppl* 2015;16: 12-16
90. Arca M. Dyslipidemia and cardiovascular risk in obesity. In *Multidisciplinary Approach to Obesity*. Lenzi A, Migliacci S Donini LM (Eds). Springer doi 10.1007/978-3-319-09045-0 ISBN 978-3-319-09044-3, pagg 121-130
91. Montali A, Truglio G, Martino F, Ceci F, Ferraguti G, Ciociola E, Maranghi M, Gianfagna F, Iacoviello L, Strom R, Lucarelli M, Arca M. Atherogenic dyslipidemia in children: evaluation of clinical, biochemical and genetic aspects. *PLoS One*. 2015 Apr 21;10(4):e0120099. doi: 10.1371/journal.pone.0120099.
92. Roberto Massa, Simone Pozzessere, Emanuele Rastelli, Laura Serra, Chiara Terracciano, Manuela Gibellini, Marco Bozzali, Marcello Arca. Neutral lipid storage disease with myopathy and prominent central nervous system involvement caused by a novel mutation in the PNPLA2 gene. *Muscle Nerve*. 2015 Nov 24. doi: 10.1002/mus.24983. [Epub ahead of print] IF=2.283
93. Minicocci I., Prisco C, Montali A, Di Costanzo A, Ceci F , Pigna G, Arca M. Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): a reappraisal by using a resequencing approach. *Atherosclerosis* (2015) http://dx.doi:10.1016/j.atherosclerosis.2015.06.036. IF=3.942
94. Martino F, Carlomosti F, Avitabile D, Persico L, Picozza M, Barilla F, Arca M, Montali A, Martino E, Zanoni C, Parrotto S, Magenta A. Circulating miR-33a and miR-33b increase in familial hypercholesterolemia in paediatric age. *Clin Sci (Lond)*. 2015 Dec;129(11):963-72. doi: 10.1042/CS20150235. Epub 2015 Jul 30 IF =5.598
95. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015 Sep 17. [Epub ahead of print] doi: 10.1056/NEJMoa1504720 IF=51.658
96. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA for the ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol* 2015; doi.org/10.1016/j.jacl.2015.08.006 IF= 3.904
97. Sentinelli F, Bertocchini L, Barchetta I, Capoccia D, Incani M, Pani MG, Loche S, Angelico F, Arca M, Morini S, Manconi E, Lenzi A, Cossu E, Leonetti F, Baroni MG, Cavallo MG. The vitamin D receptor (VDR) gene rs11568820 variant is associated with type 2 diabetes and impaired insulin secretion in Italian adult subjects, and associates with increased cardio-metabolic risk in children. *Nutr Metab Cardiovasc Dis*. 2016 Feb 19. pii: S0939-4753(15)30260-X. doi: 10.1016/j.numecd.2016.02.004. [Epub ahead of print] IF = 3.731
98. Modesti PA, Omboni S, Taddei S, Ghione S, Portaluppi F, Pozzilli P, Volpe M, Arca M, Calabrò P, Fulgheri PL, Bucci M, Berra S, Villani GO, Vladoianu M, Popescu E, Velican VG, Pirvu O. Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study. *J Hypertens*. 2016 Mar; 34(3):576-87;

- discussion 587. doi: 10.1097/HJH.0000000000000805
99. Minicocci I, Tikka A, Poggiogalle E, Metso J, Montali A, Ceci F, Labbadia G, Fontana M, Di Costanzo A, Maranghi M, Rosano A, Ehnholm C, Donini LM, Jauhiainen M, Arca M. Effects of angiotensin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. *J Lipid Res.* 2016 Apr 3. pii: jlr.P066183. [Epub ahead of print]
 100. Arca M. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): the promises of PCSK9 inhibitors. *Atherosclerosis* 2016 ; doi.org/10.1016/j.atherosclerosis.2016.09.001
 101. Minicocci I, Martino F, Pozzessere S, Prisco C, Montali A, Martino E, Marcello Arca M. Diagnostic yields of LDLR gene sequencing in children and adolescent with familial hypercholesterolemia ascertained by child-parent screening. *J of Pediatrics* (submitted) IF=3.890
 102. Ceccanti M, Cambieri C, Frasca V, Onesti E, Biasotta A, Giordano C, Bruno SM,, Testino G, Lucarelli M, Arca M, Inghilleri M. A novel mutation in ABCA1 gene causing Tangier Disease in an Italian family with uncommon neurological presentation. *Frontiers in Neurol.* 2016; 7: 185. doi: 10.3389/fneur.2016.00185
 103. Noto D, Tarugi P, Arca M, Cefalù AB, Barbagallo CM, Aversa MR Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol - diabetes connection? A systematic review of literature. *Acta Diabetol* 2016 doi: 10.1007/s00592-016-0931-4
 104. Di Costanzo A, D'Erasmo L, Polimeni L, Baratta F, Coletta P, Di Martino M, Loffredo L, Perri L, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Catalano C, Maranghi M, Del Ben M, Angelico F, Arca M. Non-alcoholic fatty liver disease and cardiovascular risk: a comparison of metabolically versus genetically-driven excess fat hepatic storage. *Atherosclerosis* (submitted)

ISTRUZIONE E FORMAZIONE

- | | |
|---|--|
| <ul style="list-style-type: none"> • Date (da – a) • Nome e tipo di istituto di istruzione o formazione • Principali materie / abilità professionali oggetto dello studio • Qualifica conseguita • Livello nella classificazione nazionale (se pertinente) | <p>1987</p> <p>Università di Roma La sapienza</p> <p>Specializzazione in Malattie del Fegato</p> |
| <ul style="list-style-type: none"> • Date (da – a) • Nome e tipo di istituto di istruzione o formazione • Principali materie / abilità professionali oggetto dello studio • Qualifica conseguita | <p>1983</p> <p>Università di Roma La sapienza</p> <p>Laurea in Medicina e Chirurgia</p> |

- Livello nella classificazione nazionale (se pertinente)

- Date (da – a)

1982 - 1985

- Nome e tipo di istituto di istruzione o formazione

Consiglio Nazionale delle Ricerche

- Principali materie / abilità professionali oggetto dello studio

Ricercatore

- Qualifica conseguita

- Livello nella classificazione nazionale (se pertinente)

- Date (da – a)

1980 1981

- Nome e tipo di istituto di istruzione o formazione

Istituto Superiore di Sanità

- Principali materie / abilità professionali oggetto dello studio

Ricercatore

- Qualifica conseguita

- Livello nella classificazione nazionale (se pertinente)

- Date (da – a)

- Nome e tipo di istituto di istruzione o formazione

Università di Roma La Sapienza

- Principali materie / abilità professionali oggetto dello studio

Training in Semeiotica Cardiovascolare

CAPACITÀ E COMPETENZE PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

MADRELINGUA

Italiano

ALTRE LINGUE

Inglese

- Capacità di lettura

Eccellente

- Capacità di scrittura

Eccellente

- Capacità di espressione orale

Eccellente

CAPACITÀ E COMPETENZE RELAZIONALI

Vivere e lavorare con altre persone, in ambiente

Ottimo

*multiculturale, occupando posti
in cui la comunicazione è
importante e in situazioni in cui
è essenziale lavorare in
squadra (ad es. cultura e
sport), ecc.*

CAPACITÀ E COMPETENZE
ORGANIZZATIVE

Ottime

*Ad es. coordinamento e
amministrazione di persone,
progetti, bilanci; sul posto di
lavoro, in attività di volontariato
(ad es. cultura e sport), a casa,
ecc.*

CAPACITÀ E COMPETENZE
TECNICHE

Ottime

*Con computer, attrezzature
specifiche, macchinari, ecc.*

CAPACITÀ E COMPETENZE
ARTISTICHE

Musica, scrittura, disegno ecc.

ALTRE CAPACITÀ E COMPETENZE

*Competenze non
precedentemente indicate.*

PATENTE O PATENTI

ULTERIORI INFORMAZIONI

ALLEGATI

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"

Data 20 febbraio 2017

Firma Marcello Arca

